Lusvendsen3627

Patients with prior cancer history are commonly excluded from clinical trial. However, the impact of prior cancer on survival of patients with gastric cancer remains largely unknown. The aim of this study was to evaluate the prevalence of prior cancer and assess its impact on survival of patients diagnosed with gastric cancer.

Patients with gastric cancer as the primary or second primary malignancies diagnosed from 2004 to 2010 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was conducted to balance baseline characteristics. Kaplan-Meier method, multivariate Cox proportional hazard model, and multivariate competing risk model were performed for survival analysis.

A total of 28,795 eligible patients with gastric cancer were included, of whom 2695 (9.35%) had a history of prior cancer. Prostate (35%), breast (12%), colon (8%), and urinary bladder (7%) malignancies were the most common prior cancer types. Patients with prior cancer history had slightly inferior overall survival (AHR=1.06; 95% CI [1.00-1.12]; P=0.043) but superior gastric cancer-specific survival (AHR=0.82; 95% CI [0.76-0.88]; P<0.001) compared with those without prior cancer. The subgroup analysis determined that a prior cancer history did not adversely affect gastric patients' clinical outcomes, except in those with prior cancer diagnosed within one year, at distant stage, or originating from lung and bronchus.

A substantial proportion of gastric cancer patients with a history of prior cancer had non-inferior clinical outcome to those without prior cancer. These patients should be considered in clinical trials.

A substantial proportion of gastric cancer patients with a history of prior cancer had non-inferior clinical outcome to those without prior cancer. These patients should be considered in clinical trials.

To quantify changes in the management of pediatric patients with isolated splenic injury from 2007 to2015.

Patients under 18 years old with registered splenic injury in the National Trauma Data Bank (2007-2015) were identified. Splenic injuries were categorized into 5 management types nonoperative management (NOM), embolization, splenic repair, splenectomy, or a combination therapy. Linear mixed models accounting for confounding variables were used to examine the direct impact of management on length of stay (LOS), intensive care unit (ICU) days, and ventilator days.

Of included patients (n= 24,128), 90.3% (n= 21,789), 5.6% (n= 1,361), and 2.7% (n= 640) had NOM, splenectomy, and embolization, respectively. From 2007 to 2015, the rate of embolization increased from 1.5% to 3.5%, and the rate of splenectomy decreased from 6.9% to 4.4%. Combining injury grades, NOM was associated with the shortest LOS (5.1 days), ICU days (1.9 days), and ventilator days (0.5 day). Moreover, splenectomy was associated with longer LOS (10.1 days), ICU days (4.5 days), and ventilator days (2.1 days) than NOM. The average failure rate of NOM was 1.5% (180 failures/12,378 cases). Average embolization failure was 1.3% (6 failures/456 cases). Splenic artery embolization was associated with lower mortality than splenectomy (OR 0.10, P <.001). No statistically significant difference was observed in mortality between embolization and NOM (OR 0.96, P= 1.0).

In pediatric splenic injury, NOM is the most utilized and associated with favorable outcomes, most notably in grades III to V pediatric splenic injury. If intervention is needed, embolization is effective and increasingly utilized most significantly in lower grade injuries.

In pediatric splenic injury, NOM is the most utilized and associated with favorable outcomes, most notably in grades III to V pediatric splenic injury. If intervention is needed, embolization is effective and increasingly utilized most significantly in lower grade injuries.

To study whether the velocity profile of horizontal saccades could be used as an indicator of brainstem and cerebellar output dysfunction, depending on progressive supranuclear palsy (PSP) subtype.

We compared the velocity profiles in 32 PSP patients of various subtypes with 38 age-matched normal subjects, including Richardson syndrome (RS), PSP-parkinsonism (PSPp), and pure akinesia (PAGF), and cerebellar subtypes of PSP (PSPc).

PSP patients showed reduced peak velocity along with increased duration, especially in the deceleration phase. This alteration was more prominent for larger target eccentricities (20-30 degrees), and correlated with disease severity. The changes were most pronounced in PSPc patients, with irregular increases and decreases in velocity profile, followed by RS patients, whereas the change was smaller in PSPp and normal in PAGF patients.

Saccade velocity profile can be an indicator of brainstem and/or cerebellar output. Altered velocity profile of PSP patients may reflect the pathology in the brainstem, but may also reflect cerebellar dysfunction, most prominently in PSPc.

Saccade velocity profile may be used as an indicator of latent cerebellar/brainstem dysfunction.

Saccade velocity profile may be used as an indicator of latent cerebellar/brainstem dysfunction.Eduard Pernkopf (1888-1955) became head of the Second Anatomical Institute in 1933, dean of the medical faculty in 1938 with the Annexation of Austria into Nazi Germany, and rector of the University of Vienna in 1943. He gained worldwide recognition with his anatomical atlas, which many consider unequaled to this day. Selleck Androgen Receptor Antagonist In the decades that followed, suspicion arose that the drawings were made using corpses of people who had been victims of Nazi persecution and, following international inquiries and critique, the University of Vienna appointed a historical commission to the matter. The commission published its results in 1998, concluding that anatomical specimens used for the illustrations in Pernkopf's atlas had in all likelihood been made using corpses of victims of the Nazi judicial system. In total, the Anatomical Institute received the corpses of at least 1377 executed people, including many members of the anti-Nazi resistance. Through the acquisition of Pernkopf's original publisher Urban & Schwarzenberg in 2003, the original drawings and the publishing rights went to Elsevier.